PALB2 and breast carcinoma: In fact, a recent phase II trial investigating Olaparib in metastatic breast cancer showed an objective response rate of 82% where there was a germline PALB2 PGV; furthermore, 85% of the breast cancers were ER-positive HER2-negative (grade not given).25